Awadhesh Kumar Singh

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6402801/publications.pdf

Version: 2024-02-01

86 papers	4,898 citations	201385 27 h-index	102304 66 g-index
90 all docs	90 docs citations	90 times ranked	8303 citing authors

#	Article	IF	Citations
1	Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 102146.	1.8	658
2	Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 303-310.	1.8	576
3	Is ethnicity linked to incidence or outcomes of covid-19?. BMJ, The, 2020, 369, m1548.	3.0	408
4	Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 211-212.	1.8	378
5	Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 241-246.	1.8	357
6	Prevalence of coâ€•morbidities and their association with mortality in patients with <scp>COVID</scp>â€•19: A systematic review and metaâ€•analysis. Diabetes, Obesity and Metabolism, 2020, 22, 1915-1924.	2.2	320
7	Role of corticosteroid in the management of COVID-19: A systemic review and a Clinicianâ€™s perspective. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 971-978.	1.8	167
8	Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 283-287.	1.8	163
9	Molnupiravir in COVID-19: A systematic review of literature. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 102329.	1.8	147
10	Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 641-648.	1.8	142
11	Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19. Diabetes Research and Clinical Practice, 2020, 167, 108382.	1.1	121
12	â€œHydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.â€• Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 589-596.	1.8	95
13	Antibody response after first and second-dose of ChAdOx1-nCOV (CovishieldTMÂ®) and BBV-152 (CovaxinTMÂ®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study. Vaccine, 2021, 39, 6492-6509.	1.7	95
14	Impact of COVID-19 and comorbidities on health and economics: Focus on developing countries and India. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 1625-1630.	1.8	90
15	Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. Expert Review of Clinical Pharmacology, 2020, 13, 53-64.	1.3	79
16	Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 181-187.	1.8	63
17	Assessment of risk, severity, mortality, glycemic control and antidiabetic agents in patients with diabetes and COVID-19: A narrative review. Diabetes Research and Clinical Practice, 2020, 165, 108266.	1.1	62
18	Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions. Indian Journal of Endocrinology and Metabolism, 2014, 18, 753.	0.2	59

#	Article	IF	Citations
19	COVID-19: From bench to bed side. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 277-281.	1.8	57
20	Diabetes insipidus: The other diabetes. Indian Journal of Endocrinology and Metabolism, 2016, 20, 9.	0.2	54
21	COVID-19 and Diabetes. Annual Review of Medicine, 2022, 73, 129-147.	5.0	52
22	Does poor glucose control increase the severity and mortality in patients with diabetes and COVID-19?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 725-727.	1.8	51
23	An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102396.	1.8	51
24	Bariatric surgery and diabetes remission: Who would have thought it?. Indian Journal of Endocrinology and Metabolism, 2015, 19, 563.	0.2	35
25	Continuous glucose monitoring results in lower HbA_{1c} in Malaysian women with insulinâ€treated gestational diabetes: a randomized controlled trial. Diabetic Medicine, 2018, 35, 1118-1129.	1.2	32
26	Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19?. Diabetes Research and Clinical Practice, 2020, 165, 108268.	1.1	31
27	Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight. Indian Journal of Endocrinology and Metabolism, 2015, 19, 722.	0.2	31
28	Triglyceride and cardiovascular risk: A critical appraisal. Indian Journal of Endocrinology and Metabolism, 2016, 20, 418.	0.2	29
29	Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 159-167.	1.8	28
30	Is gliclazide a sulfonylurea with difference? A review in 2016. Expert Review of Clinical Pharmacology, 2016, 9, 839-851.	1.3	27
31	Incretin response in Asian type 2 diabetes: Are Indians different?. Indian Journal of Endocrinology and Metabolism, 2015, 19, 30.	0.2	26
32	Humoral antibody kinetics with ChAdOx1-nCOV (Covishieldâ„¢) and BBV-152 (Covaxinâ„¢) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102424.	1.8	24
33	Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies. Expert Review of Clinical Pharmacology, 2019, 12, 299-308.	1.3	23
34	Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 93-100.	1.8	21
35	RSSDI consensus on self-monitoring of blood glucose in types 1 and 2 diabetes mellitus in India. International Journal of Diabetes in Developing Countries, 2018, 38, 260-279.	0.3	19
36	SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs. Expert Review of Clinical Pharmacology, 2017, 10, 429-442.	1.3	18

#	Article	IF	Citations
37	Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians. Diabetes Therapy, 2019, 10, 393-428.	1.2	16
38	Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 715-722.	1.8	16
39	Metformin in gestational diabetes: An emerging contender. Indian Journal of Endocrinology and Metabolism, 2015, 19, 236.	0.2	14
40	At-admission hyperglycemia is consistently associated with poor prognosis and early intervention can improve outcomes in patients with COVID-19. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 1641-1644.	1.8	14
41	Editorial: Herd mentality, herds of migrants/people, and COVID-19 in India. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 497.	1.8	14
42	Management of Type 2 diabetes in Ramadan: Low-ratio premix insulin working group practical advice. Indian Journal of Endocrinology and Metabolism, 2014, 18, 794.	0.2	13
43	Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 351-359.	1.8	13
44	Can anti-Mullerian hormone replace ultrasonographic evaluation in polycystic ovary syndrome? A review of current progress. Indian Journal of Endocrinology and Metabolism, 2015, 19, 731.	0.2	13
45	Efficacy and safety of teneligliptin. Indian Journal of Endocrinology and Metabolism, 2017, 21, 11.	0.2	13
46	Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials. Expert Review of Clinical Pharmacology, 2020, 13, 461-468.	1.3	12
47	Heart failure hospitalization with DPP-4 inhibitors: A systematic review and meta-analysis of randomized controlled trials. Indian Journal of Endocrinology and Metabolism, 2019, 23, 128.	0.2	12
48	COVID-19 associated mucormycosis: A Descriptive Multisite Study from India. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 102322.	1.8	12
49	Glucagon-like peptide 1 and dysglycemia: Conflict in incretin science. Indian Journal of Endocrinology and Metabolism, 2015, 19, 182.	0.2	11
50	Efficacy and safety of lorcaserin in obesity: a systematic review and meta-analysis of randomized controlled trials. Expert Review of Clinical Pharmacology, 2020, 13, 183-190.	1.3	11
51	Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: rationale and evidences. Expert Review of Clinical Pharmacology, 2016, 9, 409-418.	1.3	10
52	Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidence. Indian Journal of Endocrinology and Metabolism, 2016, 20, 245.	0.2	10
53	Diabetes Monotherapies versus Metformin-Based Combination Therapy for the Treatment of Type 2 Diabetes. International Journal of General Medicine, 2021, Volume 14, 3833-3848.	0.8	9
54	Consensus on Initiation and Intensification of Premix Insulin in Type 2 Diabetes Management. Journal of the Association of Physicians of India, The, 2017, 65, 59-73.	0.0	9

#	Article	IF	Citations
55	Combination therapy of sodiumâ€“glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences. Expert Review of Clinical Pharmacology, 2016, 9, 229-240.	1.3	8
56	Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach. Indian Journal of Endocrinology and Metabolism, 2014, 18, 617-23.	0.2	6
57	Modern basal insulin analogs: An incomplete story. Indian Journal of Endocrinology and Metabolism, 2014, 18, 784.	0.2	5
58	Does background metformin therapy influence the cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes?. Diabetes Research and Clinical Practice, 2021, 172, 108536.	1.1	5
59	Do SGLT â€2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?. Journal of Diabetes, 2021, 13, 596-600.	0.8	5
60	Recent cardiovascular outcome trials of antidiabetic drugs: A comparative analysis. Indian Journal of Endocrinology and Metabolism, 2017, 21, 4.	0.2	5
61	Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review. Indian Journal of Endocrinology and Metabolism, 2016, 20, 32.	0.2	4
62	Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin: rationale and evidences. Expert Review of Clinical Pharmacology, 2016, 9, 605-616.	1.3	3
63	Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh) Tj ETQq1 1 0.78431 4 rgBT /Overlock		
64	Oral semaglutide in type 2 diabetes mellitus: Comprehensive review, critical appraisal and clinical consideration of its use in India. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102436.	1.8	3
65	Polemics of pioglitazone: an appraisal in 2015. Expert Review of Endocrinology and Metabolism, 2015, 10, 447-458.	1.2	2
66	Oral antidiabetic agents in gestational diabetes: a narrative review of current evidence. Expert Review of Endocrinology and Metabolism, 2015, 10, 211-225.	1.2	2
67	Science of premix insulin: where have we reached?. Expert Review of Endocrinology and Metabolism, 2015, 10, 65-74.	1.2	2
68	Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists. Expert Review of Clinical Pharmacology, 2017, 10, 633-647.	1.3	2
69	COVID-19 experience in Kuwait: A high prevalence of asymptomatic cases and increased mortality in smokers. EClinicalMedicine, 2020, 24, 100462.	3.2	2
70	SAVOR-TIMI to DECLARE-TIMI: A review on cardiovascular outcome trials of incretin-modulators and gliflozins. Indian Journal of Endocrinology and Metabolism, 2019, 23, 175.	0.2	2
71	Hospitalisation Due to Heart Failure with Gliptins and Universal Label Change (FDA)-Still Justified? A Meta-Analysis of 5 Cardiovascular Outcomes Trials. Journal of Diabetes & Metabolism, 2018, 9, .	0.2	2
72	Advances in basal insulin therapy: lessons from current evidence. Journal of the Indian Medical Association, 2013, 111, 735-6, 738-42.	0.2	2

#	Article	IF	Citations
73	Reply to Sodium-glucose co-transporter-2 inhibitors, cardiovascular outcomes and the impact of gender: Class effect or statistical play of chance?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 335.	1.8	1
74	Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948â€“1957. Diabetes Care, 2020, 43, e200-e201.	4.3	1
75	Letter to the editor in response to the article: â€œIs diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis (Kumar etÂal.)â€. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 937-938.	1.8	1
76	Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A meta-analysis of cardiovascular outcome trials. Diabetes Research and Clinical Practice, 2021, 172, 108648.	1.1	1
77	Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients having reduced ejection fraction heart failure with type 2 diabetes, prediabetes and normoglycemia?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 102282.	1.8	1
78	Comments on: Rise of the phoenix: Mucormycosis in COVID-19 times. Indian Journal of Ophthalmology, 2021, 69, 2552.	0.5	1
79	Consensus on "Basal insulin in the management of Type 2 Diabetes: Which, When and How?". Journal of the Association of Physicians of India, The, 2017, 65, 51-62.	0.0	1
80	Expert Group Recommendations on Detection and Management of Hypoglycemia in Routine Clinical Practice in Insulin Treated Patients with Diabetes. Journal of the Association of Physicians of India, The, 2018, 66, 90-97.	0.0	1
81	Bariatric surgery and diabetes remission: how far have we progressed?. Expert Review of Endocrinology and Metabolism, 2015, 10, 545-559.	1.2	0
82	When is pharmacotherapy necessary for gestational diabetes?. Expert Opinion on Pharmacotherapy, 2021, 22, 2079-2081.	0.9	0
83	Letter in response to letter to the editor by Singh and Dhibar regarding the article â€œCOVID-19: From bench to bedsideâ€•(Singh et al.). Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 865.	1.8	0
84	Letter by Awadhesh Kumar Singh Regarding Article, â€œCardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysisâ€. Journal of Lipid and Atherosclerosis, 2022, 11, 84.	1.1	0
85	The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, , 102508.	1.8	0
86	Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors. World Journal of Diabetes, 2022, 13, 466-470.	1.3	0